文献速递肺结节与肺癌

开展立体定向体部放疗的机构中早期非小细胞肺癌手术结局

Surgical Outcomes for Early Stage Non-small Cell Lung Cancer at Facilities With Stereotactic Body Radiation Therapy Programs.
PubMed 文献 · Chest · 2021-11-14

本研究基于美国国家癌症数据库2004-2015年数据,纳入202,542例接受手术切除的cT1-T2N0M0非小细胞肺癌患者,评估机构SBRT使用情况与术后90天死亡率的关系。研究发现,SBRT经验超过6年及SBRT与手术量比值超过17%的机构,术后90天死亡率更低,提示SBRT可及性可能优化手术患者选择。

要点

  • SBRT经验>6年的机构手术患者90天死亡率更低(OR 0.84)。
  • SBRT与手术量比值>17%的机构手术患者90天死亡率更低(OR 0.85)。
  • 研究期间90天术后死亡率从4.6%降至2.6%。

核心结论

  • 在SBRT使用率较高的机构接受早期NSCLC手术切除的患者,术后死亡率更低。
  • SBRT的可及性和使用可能改善高危术后死亡风险患者的手术选择。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库2004-2015年数据。
  • 纳入202,542例接受手术切除的cT1-T2N0M0非小细胞肺癌患者。
  • 以机构SBRT经验年数和SBRT与手术量比值定义SBRT使用情况。
  • 采用多因素logistic回归分析SBRT使用与术后死亡率的关系。

主要发现

  • 研究期间90天术后死亡率从4.6%降至2.6%(P < .001)。
  • 使用SBRT的机构比例从4.6%增至77.5%(P < .001)。
  • 接受SBRT治疗的患者比例从0.7%增至15.4%(P < .001)。
  • SBRT经验>6年的机构90天术后死亡率更低(OR 0.84;95%CI 0.76-0.94;P = .003)。
  • SBRT与手术量比值>17%的机构90天术后死亡率更低(OR 0.85;95%CI 0.79-0.92;P < .001)。

临床怎么用

  • 对于早期NSCLC患者,在拥有丰富SBRT经验的机构评估手术风险可能有助于优化患者选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients undergoing surgery for early stage non-small cell lung cancer (NSCLC) may be at high risk for postoperative mortality. Access to stereotactic body radiation therapy (SBRT) may facilitate more appropriate patient selection for surgery. RESEARCH QUESTION: Is postoperative mortality associated with early stage NSCLC lower at facilities with higher use of SBRT? STUDY DESIGN AND METHODS: Patients with early stage NSCLC reported to the National Cancer Database between 2004 and 2015 were included. Use of SBRT was defined by each facility's SBRT experience (in years) and SBRT to surgery volume ratios. Multivariate logistic regression was used to test for the associations between SBRT use and postoperative mortality. RESULTS: The study cohort consisted of 202,542 patients who underwent surgical resection of cT1-T2N0M0 NSCLC tumors. The 90-day postoperative mortality rate declined during the study period from 4.6% to 2.6% (P < .001), the proportion of facilities that used SBRT increased from 4.6% to 77.5% (P < .001), and the proportion of patients treated with SBRT increased from 0.7% to 15.4% (P < .001). On multivariate analysis, lower 90-day postoperative mortality rates were observed at facilities with > 6 years of SBRT experience (OR, 0.84; 95% CI, 0.76-0.94; P = .003) and SBRT to surgery volume ratios of more than 17% (OR, 0.85; 95% CI, 0.79-0.92; P < .001). Ninety-day mortality also was associated with surgical volume, region, year, age, sex, and race, among other covariates. Interaction testing between these covariates showed negative results. INTERPRETATION: Patients who underwent resection for early stage NSCLC at facilities with higher SBRT use showed lower rates of postoperative mortality. These findings suggest that the availability and use of SBRT may improve the selection of patients for surgery who are predicted to be at high risk of postoperative mortality.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Syed YA, Stokes W, Rupji M, et al. Surgical Outcomes for Early Stage Non-small Cell Lung Cancer at Facilities With Stereotactic Body Radiation Therapy Programs. Chest. 2021. PMID: 34785235. doi:10.1016/j.chest.2021.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。